EU Launches Investigation into Experimental Lyme Disease Vaccine by Pfizer and Valneva
The Pulse Today
The European Union has agreed to study an experimental Lyme disease vaccine developed by Pfizer and Valneva, which showed a 70% efficacy rate in trials.